Eton Pharmaceuticals, Inc. (ETON) News
Filter ETON News Items
ETON News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ETON News Highlights
- ETON's 30 day story count now stands at 2.
- Over the past 1 day, the trend for ETON's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ETON are APEI, CLBT and LZ.
Latest ETON News From Around the Web
Below are the latest news stories about ETON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ETON as an investment opportunity.
5 Under-$15 Stocks Wall Street Analysts Recommend BuyingAfter a stellar rally in Wall Street this year, investors with limited funds but desire to participate in the market can bet on low-priced top-ranked stocks like Eton Pharmaceuticals (ETON), LegalZoom.com (LZ), PLAYSTUDIOS (MYPS), American Public Education (APEI) and Cellebrite DI (CLBT). |
One Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Analyst Just Made A Major Cut To Next Year's EstimatesMarket forces rained on the parade of Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders today, when the covering... |
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2023 Earnings Call TranscriptEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q3 2023 Earnings Call Transcript November 9, 2023 Eton Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.1. Operator: Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded at the company’s […] |
Declining Stock and Solid Fundamentals: Is The Market Wrong About Eton Pharmaceuticals, Inc. (NASDAQ:ETON)?Eton Pharmaceuticals (NASDAQ:ETON) has had a rough week with its share price down 16%. But if you pay close attention... |
Eton Pharmaceuticals Reports Third Quarter 2023 Financial ResultsProduct sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growthGenerated $0.9 million in positive cash flow from operations; ended quarter with $22.1 million of cash on handAcquired ultra-rare disease product Nitisinone CapsulesManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: |
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced that it will report third quarter 2023 financial results on Thursday, November 9, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT). Register* (Audio O |
Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards?Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products. |
SWK Holdings Highlights Recent Achievements and Provides Portfolio UpdateSWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower partners. |
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced it has entered into an agreement to |
Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis TherapyImmix (IMMX) gets ODD designation in the United States for lead candidate NXC-201 for the treatment of amyloid light chain (AL) Amyloidosis. |